

33 **Abstract**

34 Accurate and rapid diagnostic tools are needed for management of the ongoing coronavirus
35 disease 2019 (COVID-19) pandemic. Antibody tests enable detection of individuals past
36 the initial phase of infection and will help to examine possible vaccine responses. The
37 major targets of human antibody response in severe acute respiratory syndrome
38 coronavirus 2 (SARS-CoV-2) are the spike glycoprotein (S) and nucleocapsid protein (N).
39 We have developed a rapid homogenous approach for antibody detection termed LFRET
40 (protein L-based time-resolved Förster resonance energy transfer immunoassay). In
41 LFRET, fluorophore-labeled protein L and antigen are brought to close proximity by
42 antigen-specific patient immunoglobulins of any isotype, resulting in TR-FRET signal
43 generation.

44 We set up LFRET assays for antibodies against S and N and evaluated their diagnostic
45 performance using a panel of 77 serum/plasma samples from 44 individuals with COVID-
46 19 and 52 negative controls. Moreover, using a previously described S construct and a
47 novel N construct, we set up enzyme linked immunosorbent assays (ELISAs) for antibodies
48 against SARS-CoV-2 S and N. We then compared the LFRET assays with these enzyme
49 immunoassays and with a SARS-CoV-2 microneutralization test (MNT).

50 We found the LFRET assays to parallel ELISAs in sensitivity (90-95% vs. 90-100%) and
51 specificity (100% vs. 94-100%). In identifying individuals with or without a detectable
52 neutralizing antibody response, LFRET outperformed ELISA in specificity (91-96% vs.
53 82-87%), while demonstrating an equal sensitivity (98%).

54 In conclusion, this study demonstrates the applicability of LFRET, a 10-minute ‘mix and
55 read’ assay, to detection of SARS-CoV-2 antibodies.

56 **Introduction**

57

58 In October 2020, the number of confirmed cases in the ongoing coronavirus disease 2019
59 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2
60 (SARS-CoV-2), exceeded 40 million, with over a million deaths¹. Reliable diagnostic
61 assays are needed for specific management of COVID-19 patients as well as for epidemic
62 surveillance and containment ("Test, trace and isolate"). Nucleic acid tests (NAT) or
63 antigen tests serve to detect acute SARS-CoV-2 infection, whereas antibody testing tells
64 the past-infection and/or immunity status, at both individual and population levels. Hence,
65 antibody tests can be used for determining seroprevalences, examining vaccine responses
66 in study settings, or determining whether an individual needs a booster as in the case of
67 e.g. hepatitis B vaccine. With COVID-19, antibody testing may be the key in reaching the
68 diagnosis for a patient presenting when the viral RNA has already waned, e.g. with late
69 thromboembolic complications or prolonged symptoms². The most widespread methods in
70 antibody detection are enzyme immunoassays (EIAs) and lateral flow assays (LFAs); the
71 former tend to be highly specific and sensitive yet require dedicated infrastructure and
72 labor, and deliver the results at best within hours, whereas LFAs are simple and rapid but
73 may be of substandard diagnostic performance.

74 We have previously set up rapid homogeneous (wash-free) immunoassays utilizing time-
75 resolved Förster resonance energy transfer (TR-FRET)³⁻⁸. For FRET to occur, two
76 fluorophores, donor and acceptor, are brought to close proximity, allowing excitation of
77 the former to result in energy transfer to the latter, which then emits photons at a distinct
78 wavelength. The efficiency of FRET is inversely dependent on the distance between the
79 two fluorophores, with a 50 % efficiency typically achieved at 15 to 60 Å. To reduce
80 background from the notoriously autofluorescent biological samples, a chelated lanthanide
81 donor exhibiting long-lived fluorescence is employed, allowing for time-resolved
82 measurement (TR-FRET). We have developed a rapid homogeneous TR-FRET -based
83 immunoassay concept termed LFRET (protein L-based time-resolved Förster resonance
84 energy transfer immunoassay) and demonstrated its excellent diagnostic performance in
85 detection of antibodies against *Puumala orthohantavirus* nucleocapsid protein, *Zika virus*
86 NS1 and the autoantigen tissue transglutaminase (tTG)^{5,7,8}. LFRET relies on simultaneous

87 binding to the antibody of interest of its donor-labeled antigen and of an acceptor-labeled
88 protein L. If the patient's serum contains antibodies against the antigen, they bring the two
89 fluorophores to close proximity, generating a TR-FRET signal that indicates the presence
90 of the specific antibodies. Interestingly, a recent report describes a TR-FRET based 1-hour
91 assay for separate detection of anti-SARS-CoV-2 antibodies of different immunoglobulin
92 isotypes⁹.

93 SARS-CoV-2 is an enveloped (+)ssRNA virus with a non-segmented 30 kb genome and
94 four structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N).
95 Protruding from the viral surface are transmembrane homotrimers of S, essential for host
96 cell entry. The glycoprotein S is proteolytically cleaved into subunits S1 and S2, of which
97 S1 contains the host cell receptor-binding domain (RBD), while S2 mediates fusion with
98 the host cell membranes¹⁰. Like S, the E and M proteins are located on the viral envelope,
99 whereas N protein binds the viral RNA to form a ribonucleoprotein complex that is
100 encapsulated within the viral membrane.

101 Antibody responses to SARS-CoV-2 predominantly target the S and N proteins. In
102 hospitalized patients, the median time from onset of symptoms to IgA, IgM and IgG
103 seroconversion has been observed to be 11-14 days, with almost all individuals
104 seroconverting by day 21¹¹⁻¹³. The antibody levels correlate with the severity of disease,
105 with few patients apparently not seroconverting¹². Moreover, a fraction of the
106 seroconverters do not seem to generate detectable neutralizing antibodies¹⁴. The
107 neutralizing antibody (NAb) response correlates with the presence of anti-S antibodies^{15,16},
108 with most but not all NAb targeting the RBD¹⁷. IgG levels to other human
109 betacoronaviruses have been observed to peak within months of infection and to wane
110 within some years thereafter^{18,19}. Moreover, reinfections with seasonal human
111 coronaviruses have been observed as early as 12 months from the previous infection²⁰. As
112 for SARS-CoV-2, the persistence of antibodies and the extent to which these provide
113 protective immunity remains as of yet uncertain.

114 In this study we introduce rapid wash-free LFRET assays for detection of antibodies
115 against SARS-CoV-2 N and S antigens and compare them with ELISAs and
116 microneutralization.

117 **Results**

118

119 **LFRET incubation time, cutoff values and performance**

120 LFRET assays for SARS-CoV-2 S and N were set up using Eu-labeled in-house antigens
121 and AF-labeled protein L. First, the assay conditions were optimized separately for S and
122 N using three known anti-S/-N ELISA-positive and three known anti-S/-N ELISA-negative
123 samples (included in the full 129-sample panel). Thereafter the remaining 123 samples
124 were tested in the optimized conditions. For detection of both anti-S and anti-N antibodies
125 measurement at 7 minutes was found optimal.

126 Cutoffs for both anti-S and anti-N LFRET were set by measuring LFRET signals relative
127 to buffer in 48 samples tested negative by anti-S and anti-N ELISA. The average plus four
128 standard deviations (SD) was set as cutoff: $228.37 + 4 \times 27.59 = 338.76$ counts for anti-S
129 and $220.94 + 4 \times 27.73 = 331.86$ counts for anti-N LFRET.

130 Performances of the anti-S and anti-N LFRET assays were then determined with the 129
131 samples including 77 sera or heparin/EDTA plasmas from 44 individuals with a previous
132 RT-PCR-confirmed SARS-CoV-2 infection, four samples from four individuals negative
133 for SARS-CoV-2 by both RT-PCR and serology, and 48 samples from individuals with a
134 comprehensively negative SARS-CoV-2 serology. The sensitivities and specificities of
135 SARS-CoV-2 anti-S and anti-N LFRET in detection of PCR-positive individuals were 87%
136 and 100% & 78% and 100%, respectively. The combined anti-S/-N LFRET sensitivity and
137 specificity were 90% and 100%: if either anti-S or -N LFRET was positive, the composite
138 result was considered positive (Table 1). The development of LFRET signals over time
139 among patients with follow-up samples available is shown in Figure S1.

140 **ELISAs and microneutralization**

141 In order to compare the performance of LFRET with classical serology, we tested the set
142 of samples described above with SARS-CoV-2 anti-S and anti-N IgA, IgM and IgG
143 ELISAs as well as SARS-CoV-2 microneutralization. The panel of seronegatives was
144 excluded from anti-N IgA and IgM as well as anti-S IgM ELISAs. Altogether 107 samples

145 underwent microneutralization, including 64 samples from RT-PCR positive patients and
146 43 seronegative samples. Microneutralization titers of ≥ 20 were considered positive.

147 The ELISA cutoffs were set at average plus four standard deviations of absorbances
148 measured from 14 serum samples from SARS-CoV-2 seronegative Department staff
149 members.

150 The sensitivities and specificities of ELISA for anti-S IgA, IgG and IgM in samples from
151 SARS-CoV-2 RT-PCR-positive individuals were 91% and 98%, 90% and 100% & 66%
152 and 100%, respectively. The corresponding sensitivities and specificities of anti-N ELISA
153 were 75% and 100% (IgA), 92% and 94% (IgG) & 16% and 100% (IgM), respectively
154 (Figure S2). Pearson correlation between anti-S and anti-N IgG ELISAs was 0.90, 0.79
155 between IgM ELISAs and 0.31 between IgA ELISAs.

156 **Comparison of LFRET, ELISA and microneutralization**

157 Comparison between the LFRET signals and ELISA absorbances is presented in Figure 2.
158 For anti-N antibodies, the correlation between LFRET and IgA or IgM ELISA results was
159 low ($R=0.25$ for IgA and $R=0.13$ for IgM). With IgG ELISA a stronger correlation of
160 $R=0.62$ was seen, apparently hampered by saturation of the ELISA signal. For anti-S-
161 antibodies, correlations between IgA, IgG and IgM ELISAs were $R=0.52$, $R=0.62$ and
162 $R=0.56$, respectively. Higher LFRET signals were seen in samples from patients with
163 severe disease, especially in anti-S LFRET and when samples taken less than two weeks
164 from onset were excluded (Figure S3). The agreement between anti-N ELISA and LFRET
165 was 88-89%, and that between anti-S ELISA and LFRET 96-98% (Table S1). The samples
166 representing discordance between PCR, LFRET and/or ELISA are detailed in Table S2.

167 The LFRET and ELISA results are compared with microneutralization titers in Figure 3.
168 Spearman's rank correlation coefficient (ρ) between anti-S LFRET and MNT was 0.87,
169 whereas for anti-S IgG, IgA and IgM ELISAs it was 0.68, 0.86 and 0.81, respectively.
170 Likewise, between anti-N LFRET and MNT Spearman's ρ was 0.83, while 0.81, 0.69
171 and 0.61 for anti-N IgG, IgA and IgM ELISAs. Higher neutralization titers were observed
172 in samples from hospitalized individuals. Sensitivities and specificities of LFRET and

173 ELISA in correctly identifying microneutralization-positive and -negative samples are
174 shown in Table S3.

175 **Receiver operating characteristic analysis**

176 We also rated the performances of both LFRET assays using receiver operating
177 characteristic (ROC) curves (Figure S4). The curves were plotted in RStudio (version
178 1.3.1073) with the ROCR library (version 1.0-11). With the assumption that a positive
179 result in either IgM, IgG or IgA ELISA for a given sample signifies ‘true’ positivity, the
180 respective areas under the curve (AUCs) for both anti-N and anti-S LFRET assays were
181 very high, 0.94 and 0.97.

182 **Discussion**

183

184 We set up rapid LFRET immunoassays for detection of anti-SARS-CoV-2 S and N
185 antibodies for identification of individuals exhibiting an immune response against SARS-
186 CoV-2. Management of both COVID-19 patients and the ongoing pandemic at the
187 population level calls for accurate diagnostic tools applicable in various settings, including
188 resource poor areas without central laboratory facilities. Antibody assays allow detection
189 of individuals past the initial infection phase as well as assessment of a possible vaccine
190 response.

191 We have previously applied LFRET to diagnostics of viral and autoimmune diseases. Here,
192 we further reduced the incubation time from the prior 20-30 to 7 minutes without
193 compromising sensitivity or specificity. The simple, rapid ‘mix and read’ workflow of the
194 assay could allow faster turnaround time from sample arrival to results as well as higher
195 throughput compared to the currently popular EIAs. Moreover, the ease and speed of
196 performing LFRET makes it more feasible for use in diverse environments, including point-
197 of-care and limited-resource settings.

198 Combined anti-S/-N LFRET (i.e. if either assay is positive, the composite result is positive)
199 was equal to anti-S IgG ELISA in terms of sensitivity (90%) and specificity (100%) in
200 identification of RT-PCR -positive individuals (Table 1). Considering that the median time
201 from symptom onset to seroconversion is 1-2 weeks for SARS-CoV-2¹¹⁻¹³, we can better
202 assess the sensitivities of these assays by excluding samples taken before two weeks from
203 symptom onset. Excluding these samples, the sensitivities of anti-S, anti-N and anti-S/-N
204 LFRET are 95%, 80% and 95%, respectively. Simultaneously, the sensitivities of anti-S/-
205 N IgG ELISAs increase to 97%, 100% and 100%. Combining sensitivity and specificity
206 into a single value, the AUCs of anti-N and -S LFRET assays – 0.94 and 0.97 – reflect
207 excellent performance (Figure S4).

208 Anti-SARS-CoV-2 antibody levels are higher in patients with severe clinical
209 presentation^{12,15}. Also in our study the LFRET signals of hospitalized patients exceeded
210 those of non-hospitalized yet PCR-positive individuals (Figures 2 and S3). In the
211 hospitalized COVID-19 patients, the sensitivity of both anti-S and anti-N LFRET increased

212 to 100% by two weeks from symptom onset (Table 1), importantly for clinical use. In
213 follow-up, the LFRET signals first showed a rapid rise within three weeks from onset and
214 thereafter plateaued or slowly declined (Figure S1).

215 The agreement between ELISA and LFRET was high: ~90% for anti-N -antibodies and
216 >95% for anti-S -antibodies (Table S1). With the anti-N and anti-S LFRET vs. IgG ELISA
217 results combined, the overall agreement between the methods in the entire study material
218 was 94% (124/129 samples). A closer look at the discordance (Table S2) shows three
219 samples (65, 72 and 86) from PCR-positive individuals who remained seronegative in both
220 LFRET and ELISA, likely due to early sampling (Figure S1). Four samples (71, 70, 7 and
221 24) were negative in LFRET but positive in PCR and ELISA: The first two were early
222 infection specimens (taken 8 and 13 days post onset of symptoms) positive in anti-N IgA
223 ELISA, suggestive of early IgA seroconversion, a phenomenon observed previously²¹. The
224 other two were taken 4 and 9 weeks after onset from non-hospitalized patients positive in
225 anti-S and -N IgG and/or IgA ELISAs. These ELISA reactivities were weak (Figure 2e),
226 suggesting that the negativity in LFRET might reflect lower analytical sensitivity. Two
227 samples (82, 92) were negative in LFRET and RT-PCR but positive in anti-N IgG ELISA.
228 Additionally, two samples (103, 121) were negative in LFRET and MNT, but positive in
229 either anti-N IgG ELISA or anti-S IgA ELISA. No false positives were observed in
230 LFRET.

231 In microneutralization, all but one of the reactive samples were also positive in anti-S
232 LFRET, IgG and IgA ELISA and anti-N IgG ELISA (Figure 3), the exception being an
233 ICU patient sampled 13 days after onset with an MNT titer of 20 and a positive anti-N IgA
234 ELISA (Table S2, sample 70). Some of the studied individuals who seroconverted did not
235 exhibit a detectable neutralizing antibody response, as observed previously¹⁴. Interestingly,
236 the specificities of the LFRET assays in identification of the non-neutralizing individuals
237 as negatives (91% for S and 96% for N) were higher than those of IgG ELISAs (87% for
238 S and 82% for N) (Table S3). This may be due to lower analytical sensitivity of LFRET,
239 as the undetectable neutralization could result from lower overall levels of anti-SARS-
240 CoV-2 antibodies in the LFRET-negative but ELISA-positive samples. Nevertheless,
241 among the assays evaluated, anti-S LFRET demonstrated the best overall performance in

242 identification of samples containing neutralizing antibodies, with a sensitivity of 98% and
243 a specificity of 91%.

244 Our study has some limitations. First, our SARS-CoV-2 -positive samples originated from
245 symptomatic patients. Individuals with asymptomatic infection may mount a significantly
246 lower antibody response²², whereby the sensitivity of LFRET in such individuals might be
247 lower. A second limitation is that antibodies against other coronaviruses, especially the
248 widely circulating OC43, HKU1, NL63 and 229E, were not examined. Those antibodies
249 potentially cross-reacting in the SARS-CoV-2 assay could reduce its specificity. However,
250 the RT-PCR and neutralization results strongly indicate that the observed antibody
251 responses were SARS-CoV-2-specific.

252 In conclusion, this study demonstrates the applicability of the LFRET approach to
253 detection of SARS-CoV-2 antibodies. While in sensitivity and specificity the assay
254 appears to parallel ELISA, the new assay is as easy and rapid to perform as an LFA,
255 requiring only combination of the diluted sample with a reagent mix and reading the
256 result after 7 minutes. In prediction of neutralization capacity, the anti-S LFRET
257 outperformed ELISA in specificity, at equal sensitivity.

258 **Materials and Methods**

259

260 **Samples**

261 This study included 77 serum/plasma samples from 40 individuals tested positive and four
262 samples from four individuals tested negative for SARS-CoV-2 by RT-PCR from
263 nasopharyngeal swab samples. The positive samples were taken at 8 to 81 days after onset
264 of symptoms. Additionally, 48 serum samples from asymptomatic individuals with a
265 comprehensively negative SARS-CoV-2 serology (Euroimmun IgG, IFA IgG virus, IFA
266 IgG spike, microneutralization negative) were included in the study. The data and samples
267 were collected under research permit HUS/211/2020 and ethics committee approval
268 HUS/853/2020 (Helsinki University Hospital, Finland).

269 **Nucleic acid testing**

270 Nucleic acid testing for SARS-CoV-2 was done from nasopharyngeal swab samples with
271 either the Cobas® SARS-CoV-2 test using the Cobas® 6800 system (Roche Diagnostics,
272 Basel, Switzerland), a protocol based on one previously described by Corman et al.²³, or
273 the Amplidiag® COVID-19 test (Mobidiag, Espoo, Finland).

274 **Molecular cloning**

275 For protein expression, we acquired the ZeoCassette Vector (pCMV/Zeo) from
276 ThermoFisher Scientific, and excised the Zeocin resistance gene from the vector using
277 FastDigest EcoRI and XhoI (ThermoFisher Scientific) according to manufacturer's
278 protocol. The excised gene was agarose gel purified, blunted using T4 DNA polymerase
279 (ThermoFisher Scientific), and purified using Ampure XP beads (Beckman Coulter) both
280 following the manufacturer's protocol. The selection gene was inserted into
281 pCAGGS/MCS and to the pCAGGS vector bearing SARS-CoV-2 S protein (described in
282 ^{24,25}) gene by treating the plasmids with FastDigest SapI/LguI (ThermoFisher Scientific)
283 according to manufacturer's protocol, followed by blunting and purifications as above. The
284 insert was ligated to the plasmids using T4 DNA ligase (ThermoFisher Scientific)
285 according to manufacturer's protocol, the ligation products transformed into *Escherichia*
286 *coli* (DH5a strain), followed by plating the bacteria onto LB plates with 100 µg/ml of

287 ampicillin and 50 µg/ml Zeocin (ThermoFisher Scientific). After overnight incubation at
288 37 °C, single colonies were picked and grown in 5 ml of 2xYT medium supplemented with
289 100 µg/ml of ampicillin and 50 µg/ml Zeocin overnight at 37 °C. The plasmids were
290 purified using GeneJET Plasmid Miniprep Kit (ThermoFisher Scientific), and plasmids
291 bearing the insert identified by restriction digestion (FastDigest EcoRI, ThermoFisher
292 Scientific) and agarose gel electrophoresis. For both constructs, clones with the insert in
293 reverse and forward direction were selected for ZymoPURE II Plasmid Maxiprep Kit
294 (ZymoResearch) preparations done following manufacturer's guidelines. A synthetic
295 SARS-CoV-2 NP gene under Kozak sequence and a signal sequence
296 MMRPIVLVLLFATSALA flanked by KpnI and SgsI restriction sites was obtained from
297 ThermoFisher Scientific. The SARS-CoV-2 NP cassette was subcloned into
298 pCAGGS/MCS-Zeo-fwd vector and plasmid maxipreps prepared as described above.

299 **Protein expression and purification**

300 We initially attempted producing SARS-CoV-2 S protein in Expi293F cells utilizing the
301 Expi293 Expression System (ThermoFisher Scientific). Briefly, the pCAGGS plasmid
302 bearing codon-optimized SARS-CoV-2 spike²⁴ was transiently transfected into Expi293F
303 cells as advised^{24,25}, except that we used spinner flasks (disposable 125 ml spinner flask,
304 Corning) for the culture. Protein purification from supernatants collected at five days post
305 transfection followed the protocol described²⁵ and yielded 0.2-0.3 mg per 100 ml culture,
306 in line with earlier reports^{24,25}.

307 Next, we transfected adherent HEK293T cells with pCAGGS-SARS-CoV-S-Zeo plasmids
308 using Fugene HD at 3.5:1 ratio, in suspension as described²⁶. The transfected cells were
309 plated onto six-well plates, and at 48 h post transfection subjected to Zeocin selection, 150
310 µg/ml Zeocin in high glucose DMEM (Dulbecco's Modified Eagle's Medium, Sigma)
311 supplemented with 5% fetal bovine serum (Gibco) and 4 mM L-glutamine. Two days after
312 initiating the selection, the cells were trypsinized and transferred into fresh wells, with
313 fresh media and antibiotics provided at 2 to 3 day intervals. Once confluent, the cells were
314 trypsinized, counted (TC20 cell counter, Bio-Rad), diluted to ~30 cells/ml, and dispensed
315 onto 96-well plates, 100 µl per well. After confluency, we switched to serum-free FreeStyle
316 293 Expression Medium (ThermoFisher Scientific) with 100 µg/ml Zeocin, and incubated

317 the cells at 37 °C 5% CO₂. At 48 h, we analyzed the medium for the presence of SARS-
318 CoV-2 S protein by dot blotting, briefly 2.5 µl of the supernatant was dried onto a
319 nitrocellulose membrane, the membrane blocked (3% skim milk in Tris-buffered saline
320 with 0.05% Tween-20), washed, probed with rabbit anti-RBD (Sino Biological, 40592-
321 T62), washed, probed with anti-rabbit IRDye800 (LI-COR Biosciences), washed, and read
322 using Odyssey Infrared Imaging System (LI-COR Biosciences). The clone with the highest
323 amount of SARS-CoV-2 S protein in the cell culture supernatant, HEK293T-spike-D5, was
324 then expanded in DMEM with 5% FBS, 4 mM L-glutamine and 100 µg/ml Zeocin, and
325 ampouled for storage in liquid nitrogen. We adapted the HEK293T-spike-D5 cells for
326 suspension culture by placing trypsinized cells into a spinner flask with Expi293
327 Expression Medium (ThermoFisher Scientific) with 100 µg/ml of Zeocin. We stored an
328 aliquot of the adapted cells in liquid nitrogen and tested their ability to produce SARS-
329 CoV-2 S protein in both Expi293 and FreeStyle 293 Expression Medium (both
330 ThermoFisher Scientific). Having been cultured in the spinner flask for 5 to 8 days, the
331 cells reached a density of $>3 \times 10^6$ cells/ml. The protein from the supernatants was purified
332 using the protocol described²⁵, with yields of 0.8-1.2 mg per 100 ml culture.

333 For production of SARS-CoV-2 N protein, we transfected Expi293F cells with pCAGGS-
334 SARS-CoV-2-NP-Zeo using Fugene HD, briefly, 100 µg of the plasmid diluted into 10 ml
335 of OptiMEM (Sigma), 350 µl of Fugene HD added followed by mixing and 15 min
336 incubation at room temperature, after which the plasmid mix was added onto Expi293F
337 cells in Expi293 Expression Medium at 2.5×10^6 cells/ml. The incubation of the transfected
338 cells was continued for four days, after which the supernatant was collected, and the protein
339 purified (yield approximately 1 mg per 100 ml culture) as described for S protein²⁵. The
340 remaining cells were treated with 0.25% Trypsin-EDTA (Sigma) to remove dead cells, and
341 after two washes were put back into the spinner flask with fresh Expi293 Expression
342 Medium supplemented with 100 µg/ml of Zeocin. Eventually a population of cells started
343 to proliferate (Expi-NP-zeo cells), and were aliquoted in liquid nitrogen. The protein
344 production and purification occurred as described above with yields of ~1 mg per 100 ml
345 culture.

346 **Protein labeling**

347 We labeled the SARS-CoV-2 S and N proteins with the donor fluorophore europium (Eu)
348 using QuickAllAssay Eu-chelated protein labeling kit (BN Products and Services Oy)
349 according to the manufacturer's instructions to generate Eu-labeled S (Eu-S) and N (Eu-
350 N). We also labeled recombinant protein L (Thermo Scientific) with the acceptor
351 fluorophore Alexa Fluor 647 to generate AF647-labeled protein L (AF-L), as reported⁵.
352 IgG-free bovine serum albumin (BSA) was from Jackson ImmunoResearch Inc.

353 **TR-FRET assays**

354 The LFRET assay was done as described⁵ and as briefly illustrated by the flowchart in
355 Figure 1. For calculating the relative TR-FRET signal increase, we here replace the pool
356 of negative sera with TBS-BSA (50mM Tris-HCl, 150mM NaCl, pH 7.4, 0.2% BSA). To
357 establish LFRET assays for S and N, we optimized the component concentrations by cross-
358 titration using three positive and three negative serum samples. For detection of anti-N
359 antibodies, we found the optimal on-plate dilution for serum to be 1/25, and the optimal
360 on-plate concentrations for AF-L and Eu-N to be 500 nM and 5 nM, respectively. For
361 detection of anti-S antibodies, we found an on-plate dilution of 1/100 for serum, AF-L
362 concentration of 250 nM and Eu-S concentration of 5 nM optimal. We measured TR-FRET
363 at 0, 7, 15, 22, 30, 45 and 60 minutes after combining the reagents. TR-FRET counts were
364 measured with Wallac Victor² fluorometer (PerkinElmer) and normalized as described³.

365 **Enzyme linked immunosorbent assays (ELISAs)**

366 We set up the SARS-CoV-2 S protein ELISA as described²⁵ with the following
367 amendments. We coated the plates (ThermoScientific NUNC-immuno 446442 polysorp
368 lockwell C8) with 50 ul/well of antigens diluted 1 µg/ml into 50 mM carbonate-bicarbonate
369 buffer pH 9.6 (Medicago AB) and used 1-Step Ultra TMB-ELISA Substrate Solution
370 (ThermoFisher Scientific). As secondary antibodies we made use of polyclonal rabbit anti-
371 human IgA-horse radish peroxidase (HRP), -IgM-HRP, and -IgG-HRP (all from Dako) at
372 respective dilutions of 1:5000, 1:1500, and 1:6000. The colorimetric reaction was
373 terminated by addition to 0.5 M sulphuric acid (Fluka), and the absorbances recorded
374 (HIDEX Sense) at 450 nm. The N protein ELISA followed the same protocol.

375 **Microneutralization**

376 For the SARS-CoV-2 microneutralization assay we first cultured Vero E6 cells on 96-
377 well plates (Thermo Scientific) overnight at +37°C in 2% MEM (Eagle Minimum
378 Essential Media [Sigma-Aldrich] supplemented with 2% inactivated fetal bovine serum
379 [Thermo Scientific], 2 mM L-glutamine [Thermo Scientific], 100 units penicillin, and
380 100 µg/ml streptomycin [Sigma-Aldrich]). The following day we made a two-fold
381 dilution series (1:20 to 1:1280) of the serum samples in 2% MEM and combined 50 µl of
382 each dilution with 50 µl of virus (1000 plaque forming units (pfu)/ml in 2% MEM). The
383 serum-virus mixes were kept for 1h at +37°C. The cells were inoculated with the serum-
384 virus mixes and grown in incubators at +37°C. After 4 days, the cultures were fixed with
385 formalin, stained with crystal violet and the neutralization titers recorded.

386 **Acknowledgments and funding information**

387

388 The authors wish to acknowledge Drs. Tomas Strandin and Eliisa Kekäläinen for helping
389 in sample collection. Reagent generation in the Krammer laboratory was supported by the
390 NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract
391 HHSN272201400008C and the Collaborative Influenza Vaccine Innovation Centers
392 (CIVIC) contract 75N93019C00051.

393

394 The authors received funding for this work from the following sources: the Sigrid
395 Jusélius Foundation, the Magnus Ehrnrooth Foundation, Finnish Society of Sciences and
396 Letters, the Research Funds of University of Helsinki and Helsinki University Hospital
397 (TYH 2018322), Finska Läkaresällskapet, the Finnish Medical Foundation, Academy of
398 Finland (#1308613, #1336490, #336439 and #335527), Juho Vainio Foundation, Jane
399 and Aatos Erkko Foundation, the European Union Horizon 2020 programme VEO
400 (Versatile emerging infectious disease observatory, grant No. 874735) and from Private
401 donors through the University of Helsinki.

402 References


- 403 1. WHO, Coronavirus disease (COVID-19) Weekly Epidemiological Update.
404 [https://www.who.int/publications/m/item/weekly-epidemiological-update---27-](https://www.who.int/publications/m/item/weekly-epidemiological-update---27-october-2020)
405 [october-2020](https://www.who.int/publications/m/item/weekly-epidemiological-update---27-october-2020) (27 October 2020).
- 406 2. J. Watson, A. Richter, J. Deeks. Testing for SARS-CoV-2 antibodies. *BMJ*.
407 <https://doi.org/10.1136/bmj.m3325> (8 September 2020).
- 408 3. S. Saraheimo et al., Time-resolved FRET -based approach for antibody detection -
409 a new serodiagnostic concept. *PLoS One*. **8**, e62739 (2013).
- 410 4. S. Hepojoki et al., A protein L-based immunodiagnostic approach utilizing time-
411 resolved Förster resonance energy transfer. *PLoS One*. **9**, e106432 (2014).
- 412 5. S. Hepojoki, J. Hepojoki, K. Hedman, O. Vapalahti, A. Vaeheri, Rapid
413 homogeneous immunoassay based on time-resolved Förster resonance energy
414 transfer for serodiagnosis of acute hantavirus infection. *J Clin Microbiol*. **53**, 636–
415 640 (2015).
- 416 6. S. Hepojoki et al., Competitive Homogeneous Immunoassay for Rapid
417 Serodiagnosis of Hantavirus Disease. *J Clin Microbiol*. **53**, 2292–2297 (2015).
- 418 7. L. Kareinen et al., Immunoassay for serodiagnosis of Zika virus infection based on
419 time-resolved Förster resonance energy transfer. *PLoS One*. **14**, e0219474 (2019).
- 420 8. J. Rusanen et al., LFRET, a novel rapid assay for anti-tissue transglutaminase
421 antibody detection. *PLoS One*. **14**, e0225851 (2019).
- 422 9. Y. Hong et al., Rapid 'mix and read' assay for scalable detection of SARS-CoV-2
423 antibodies in patient plasma. *medRxiv*.
424 <https://doi.org/10.1101/2020.09.01.20184101> (3 September 2020).
- 425 10. A.C. Walls et al., Structure, Function, and Antigenicity of the SARS-CoV-2 Spike
426 Glycoprotein. *Cell*. **181**, 281–292.e6 (2020).
- 427 11. J. Zhao et al., Antibody responses to SARS-CoV-2 in patients of novel coronavirus
428 disease 2019. *Clin Infect Dis*. <https://doi.org/10.1093/cid/ciaa344> (28 May 2020).
- 429 12. Q.X. Long et al., Antibody responses to SARS-CoV-2 in patients with COVID-19.
430 *Nat Med*. **26**, 845–848 (2020).
- 431 13. P.H. Herroelen, G.A. Martens, D. De Smet, K. Swaerts, A.S. Decavele, Humoral
432 Immune Response to SARS-CoV-2. *Am J Clin Pathol*. **154**, 610–619 (2020).
- 433 14. F. Wu et al., Evaluating the Association of Clinical Characteristics With
434 Neutralizing Antibody Levels in Patients Who Have Recovered From Mild
435 COVID-19 in Shanghai, China. *JAMA Intern Med*. **180**, 1356–1362 (2020).
- 436 15. N.M.A Okba et al., Severe Acute Respiratory Syndrome Coronavirus 2-Specific
437 Antibody Responses in Coronavirus Disease Patients. *Emerg Infect Dis*. **26**, 1478–
438 1488 (2020).
- 439 16. P.M. Folegatti et al., Safety and immunogenicity of the ChAdOx1 nCoV-19
440 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind,
441 randomised controlled trial. *Lancet*. **396**, 467–478 (2020).
- 442 17. P.J.M. Brouwer et al., Potent neutralizing antibodies from COVID-19 patients
443 define multiple targets of vulnerability. *Science*. **369**, 643–650 (2020).
- 444 18. H.M. Al-Abdely et al., Middle East Respiratory Syndrome Coronavirus Infection
445 Dynamics and Antibody Responses among Clinically Diverse Patients, Saudi
446 Arabia. *Emerg Infect Dis*. **25**, 753–766 (2019).

- 447 19. W.C. Cao, W. Liu, P.H. Zhang, F. Zhang, J.H. Richardus, Disappearance of
448 antibodies to SARS-associated coronavirus after recovery. *N Engl J Med.* **357**,
449 1162–1163 (2007).
- 450 20. A.W.D Edridge et al., Seasonal coronavirus protective immunity is short-lasting.
451 *Nat Med.* <https://doi.org/10.1038/s41591-020-1083-1> (14 September 2020).
- 452 21. A.J. Jääskeläinen et al., Evaluation of commercial and automated SARS-CoV-2
453 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples. *Euro*
454 *Surveill.* **25**, 2000603 (2020).
- 455 22. Q.X. Long et al., Clinical and immunological assessment of asymptomatic SARS-
456 CoV-2 infections. *Nat Med.* **26**, 1200–1204 (2020).
- 457 23. V.M. Corman et al., Detection of 2019 novel coronavirus (2019-nCoV) by real-
458 time RT-PCR. *Euro Surveill.* **25**, 2000045 (2020).
- 459 24. F. Amanat et al., A serological assay to detect SARS-CoV-2 seroconversion in
460 humans. *Nat Med.* **26**, 1033–1036 (2020).
- 461 25. D. Stadlbauer et al., SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol
462 for a Serological Assay, Antigen Production, and Test Setup. *Curr Protoc*
463 *Microbiol.* **57**, e100 (2020).
- 464 26. L Szirovicza et al., Snake Deltavirus Utilizes Envelope Proteins of Different
465 Viruses To Generate Infectious Particles. *mBio.* 11, e03250-19 (2020).

466 **Figures and Tables**


467

SARS-CoV-2 N-/S-LFRET




468

469 **Figure 1.** Simplified protocol for SARS-CoV-2 N and S LFRET assay. Eu-N/-S =
470 Europium-labeled nucleocapsid protein/spike glycoprotein. AF-L = Alexa Fluor™ 647 -
471 labeled protein L. TR-FRET = time-resolved Förster resonance energy transfer. RT =
472 room temperature. TBS+BSA (50mM Tris-HCl, 150mM NaCl, pH 7.4, 0.2% BSA) was
473 used for all dilutions. On-plate dilutions were 5 nM Eu-N/500 nM AF-L/serum 1/25 for
474 anti-N and 5 nM Eu-S/250 nM AF-L/serum 1/100 for anti-S LFRET. For further details
475 see the prior publication⁵.



476
 477 **Figure 2.** ELISA (x-axis) vs. LFRET (y-axis) results by disease severity. a) Anti-N IgA ELISA vs. anti-N LFRET (N=81, R=0.25). b) anti-N IgG ELISA vs. anti-N LFRET (N=129, R=0.62). c) anti-N IgM ELISA vs.
 478 anti-N LFRET (N=81, R=0.13). d) anti-S IgA ELISA vs. anti-S LFRET (N=129, R=0.53). e) anti-S-IgG ELISA vs. anti-S LFRET (N=129, R=0.62). f) anti-S IgM ELISA vs. anti-S LFRET (N=81, R=0.56). Colour of
 479 the dot indicates SARS-CoV-2 PCR result and disease severity: cyan = PCR negative; yellow = non-hospitalized, PCR-positive; red = non-ICU hospitalized, PCR positive; black = hospitalized in ICU, PCR positive.
 480 Horizontal and vertical black lines indicate LFRET and ELISA cutoffs. On the X-axis, ELISA absorbance on a logarithmic scale and on the y-axis, LFRET signal on a logarithmic scale. S = spike glycoprotein. N =
 481 nucleocapsid protein. LFRET = protein L-based time-resolved Förster resonance energy transfer immunoassay. ELISA = enzyme immunoassay. R = Pearson's correlation coefficient.



483 **Figure 3.** Microneutralization vs. LFRET and ELISA. Microneutralization titers are on the x-axis and LFRET signal or ELISA
 484 absorbance on the y-axis. Logarithmic scale is used on both axes. a) Microneutralization titer vs. anti-S LFRET signal (N=107, $\rho=0.87$).
 485 b-d) Microneutralization titer vs. anti-S IgG, IgA and IgM ELISA (N=107, 107 and 67, $\rho=0.68$, 0.86 and 0.81). e) Microneutralization
 486 titer vs. anti-N LFRET signal (N=107, $\rho=0.83$). f-h) Microneutralization titer vs. anti-N IgG, IgA and IgM ELISA (N=107, 67 and 67,
 487 $\rho=0.81$, 0.69 and 0.61). Colour of the dots indicate SARS-CoV-2 PCR result and disease severity: cyan = PCR negative; yellow = non-
 488 hospitalized, PCR-positive; red = non-ICU hospitalized, PCR positive; black = hospitalized in ICU, PCR positive. Horizontal black lines
 489 indicate LFRET/ELISA cutoffs. S = spike glycoprotein. N = nucleocapsid protein. LFRET = protein L-based time-resolved Förster
 490 resonance energy transfer immunoassay. ELISA = enzyme immunoassay. ρ = Spearman's rank correlation coefficient.
 491

492 **Table 1.** Sensitivity and specificity of ELISA and LFRET in detection of SARS-CoV-
 493 2 -PCR-positive individuals for all patients and hospitalized patients at different time
 494 points from symptom onset. Altogether twenty samples from ten PCR-positive
 495 individuals for whom the onset of symptoms is unknown are excluded. Specificity is
 496 calculated from non-hospitalized asymptomatic individuals. N = nucleocapsid protein.
 497 S = spike glycoprotein. LFRET = protein L-based time-resolved Förster resonance
 498 energy transfer immunoassay. ELISA = enzyme-linked immunosorbent assay.

Patient group	S LFRET sensitivity / specificity			S IgG ELISA sensitivity / specificity		
	All samples	>8 days after onset	>13 days after onset	All samples	>8 days after onset	>13 days after onset
All patients	87% / 100%	92% / 100%	95% / 100%	90% / 100%	96% / 100%	100% / 100%
Hospitalized	83% / 100%	92% / 100%	100% / 100%	83% / 100%	92% / 100%	100% / 100%
	N LFRET sensitivity / specificity			N IgG ELISA sensitivity / specificity		
All patients	78% / 100%	81% / 100%	80% / 100%	92% / 94%	98% / 94%	100% / 94%
Hospitalized	79% / 100%	92% / 100%	100% / 100%	86% / 94%	96% / 94%	100% / 94%
	S/N LFRET sensitivity / specificity			S/N IgG ELISA sensitivity / specificity		
All patients	90% / 100%	94% / 100%	95% / 100%	92% / 94%	98% / 94%	100% / 94%
Hospitalized	86% / 100%	96% / 100%	100% / 100%	86% / 94%	96% / 94%	100% / 94%